---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-22-000011"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:38:26.913008+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q3 net loss $47.8M; announces zanidatamab deal with Jazz up to $1.76B

## Summary
- Licensed zanidatamab to Jazz for up to $1.76B total payments plus 10-20% tiered royalties; $50M upfront expected 4Q22.
- Q3 revenue $2.6M (down from $4.4M), net loss $47.8M (vs $60.6M YoY).
- Cash $166.2M; Jazz upfront extends cash runway through at least 2026.
- Phase 1 zanidatamab zovodotin showed 31% ORR at 2.5 mg/kg Q3W; manageable tolerability.
- Aims to file 5 INDs in next 5 years; IND for ZW191 (FRα-ADC) expected 2024.

## SEC filing metadata
- accession: 0001937653-22-000011
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/0001937653-22-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/zyme-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-22-000011
- JSON: https://secwatch.observer/filing/0001937653-22-000011.json
- Plain text: https://secwatch.observer/filing/0001937653-22-000011.txt

## Key facts
- Earnings Releases
  Zymeworks Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: today reported financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000193765322000011/0001937653-22-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.